Who Owns Dermapharm Holding Company?

Dermapharm Holding Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Dermapharm Holding?

Understanding a company's ownership structure is crucial for investors and stakeholders alike. The evolution of ownership, especially after pivotal events like an IPO, can significantly impact a company's strategic direction and performance. This is particularly relevant when examining a dynamic player in the healthcare sector like Dermapharm Holding SE. What are the key factors influencing Dermapharm Holding SWOT Analysis and its ownership?

Dermapharm, a prominent German pharmaceutical company, has a fascinating ownership journey. Founded in 1991 by Wilhelm Beier, the company has transformed from a privately held entity to a publicly traded company. This exploration will examine the key players in Dermapharm's ownership, including its founders, major shareholders, and the impact of its IPO on the company's governance and strategic outlook. Understanding who owns Dermapharm provides valuable insights into its future.

The story of Dermapharm Holding begins with its founder, Wilhelm Beier. He established the company in 1991, marking the start of what would become a significant player in the pharmaceutical industry. Mr. Beier's background in the field, starting in 1981, provided a strong foundation for the company's early development and strategic direction.

Initially, the ownership of Dermapharm Holding was concentrated within the Beier family. They held the majority of the shares through Themis Beteiligungs AG, setting the stage for the company's initial growth phase. This concentrated ownership structure was a key characteristic of Dermapharm in its early years.

The evolution of Dermapharm's ownership structure is a key aspect of its history. The company's journey from a privately held entity to a publicly traded one reflects its growth and changing financial landscape. Understanding the ownership dynamics is crucial for anyone looking into Dermapharm's history and future.

Wilhelm Beier's Role

Wilhelm Beier founded Dermapharm Holding in 1991. He served as the Chief Executive Officer of Dermapharm AG before becoming the chairman of the supervisory board in 2017. His experience in the pharmaceutical industry was instrumental in the company's early success.

Early Ownership Structure

At the company's inception, the Beier family held the majority of Dermapharm's shares. This ownership was managed through Themis Beteiligungs AG. This structure provided a solid base for the company's initial growth and strategic decisions.

IPO Impact

The IPO in 2018 marked a significant change in Dermapharm's ownership. The Beier family sold a portion of their shares, but retained a substantial stake. This event brought in new investors and increased the company's visibility.

IPO Details

The IPO took place on February 9, 2018. The offer price was EUR 28.00 per share. The IPO included both new shares and shares from the Beier family's holdings.

Share Distribution Post-IPO

After the IPO, Themis Beteiligungs-Aktiengesellschaft remained the majority shareholder. The free float, representing shares available to the public, was approximately 25%. This distribution reflects the shift in ownership after the IPO.

Public Offering

The IPO involved the placement of 13,455,000 shares. This included both new shares issued by the company and shares sold by the Beier family. This offering was a crucial step in Dermapharm's growth.

Key Takeaways on Dermapharm's Ownership

The ownership structure of Dermapharm has evolved significantly since its founding. From the initial majority ownership by the Beier family to the partial public offering, the company's journey reflects its growth and strategic decisions. The IPO in 2018 was a pivotal moment, changing the ownership landscape and opening new avenues for growth. To understand more about Dermapharm's strategic direction, consider reading about the Growth Strategy of Dermapharm Holding.

• Wilhelm Beier founded Dermapharm Holding in 1991.
• The Beier family initially held the majority of shares through Themis Beteiligungs AG.
• The IPO in 2018 saw the Beier family sell a portion of their shares.
• Post-IPO, Themis Beteiligungs-Aktiengesellschaft remained the majority shareholder.
• The IPO involved the placement of 13,455,000 shares at EUR 28.00 per share.

Dermapharm Holding SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Dermapharm Holding has evolved since its initial public offering (IPO) in 2018. The founder, Wilhelm Beier, and his family, through Themis Beteiligungs-Aktiengesellschaft, continue to hold a significant majority stake. This has been a defining factor in the company's ownership dynamics. This significant holding by the founder suggests a potential for the company to go private.

The IPO established a free float of roughly 25% and an initial market capitalization of about EUR 1.5 billion. The founder's actions and institutional investments have shaped the company's ownership landscape. Key events have influenced the ownership structure, including secondary offerings and insider transactions. For a deeper understanding of the company's financial workings, consider reading about Revenue Streams & Business Model of Dermapharm Holding.

Major institutional investors also play a role in Dermapharm's ownership. As of May 2023, Mawer Investment Management Ltd. held a notable stake. Other significant shareholders include The Vanguard Group, Inc. and BlackRock, Inc. These institutional holdings, along with the founder's majority stake, influence the company's governance and strategic decisions. As of March 2025, Wilhelm Beier and his family, through Themis Beteiligungs AG, hold over a 70% stake in the company, with some reports indicating this stake to be as high as 77.1% as of May 2025.

Key Ownership Facts

The founder and his family maintain a controlling interest in Dermapharm.

• The IPO in 2018 set the initial ownership structure.
• Institutional investors hold significant stakes, influencing governance.
• Wilhelm Beier's family holds a majority stake, potentially impacting future strategies.
• The free float has changed due to secondary offerings and insider transactions.

Dermapharm Holding PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The governance of Dermapharm Holding is structured around a Supervisory Board and a Management Board. The Supervisory Board is chaired by Wilhelm Beier, the founder. Other key members include Dr. Erwin Kern, who serves as the Independent Vice Chairman, and Lothar Lanz, an Independent Member.

The Management Board includes Dr. Hans-Georg Feldmeier as the Chief Executive Officer and Chairman, Christof Dreibholz as Chief Financial Officer and Chief Compliance Officer, and Dr. Andreas Eberhorn as Chief Marketing Officer. This structure is crucial for understanding the decision-making processes within the company and how Dermapharm ownership is managed.

The voting power within Dermapharm is significantly influenced by the ownership structure. Wilhelm Beier and his family, through Themis Beteiligungs AG, hold a majority stake. Recent reports (March-May 2025) indicate this entity controls over 70%, potentially up to 77.1%, of the shares. This substantial holding gives the founder considerable control, reflecting a 'one-share-one-vote' system. Annual general meetings, such as the one scheduled for June 26, 2025, are key for exercising these voting rights. Understanding Dermapharm Holding Company shareholders is vital for anyone assessing the company's strategic direction.

Key Takeaways on Dermapharm's Governance

Dermapharm's governance is shaped by its board structure and major shareholder influence.

• Wilhelm Beier, the founder, chairs the Supervisory Board.
• Themis Beteiligungs AG, owned by the Beier family, holds a significant majority stake.
• The voting structure is primarily 'one-share-one-vote,' with the majority shareholder wielding considerable power.
• Understanding Dermapharm ownership is essential for investors and stakeholders.

Dermapharm Holding Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, several key developments have influenced the ownership landscape of Dermapharm Holding. A significant trend is the continued dominance of founder Wilhelm Beier. As of March 2025, Beier and his family, through Themis Beteiligungs AG, control over 70% of the shares, with some reports suggesting a stake as high as 77.1% by May 2025. This substantial ownership concentration has fueled speculation about the potential for the company to go private. Recent insider trading further supports this trend, with Themis Beteiligungs-Aktiengesellschaft making notable share purchases, including 1,800,000 shares for approximately EUR 73.22 million in March 2025. This activity, coupled with purchases by other insiders, reflects confidence from within the company's leadership.

The company's strategic acquisitions also play a role in shaping its overall value and investor appeal. In February 2020, Dermapharm acquired Allergopharma. Early 2022 saw the acquisition of the C³ Group, a medical cannabis company. Moreover, in June 2023, Dermapharm acquired a significant stake in Montavit. These moves, while not directly changing the core ownership percentages, contribute to the company's valuation and attract potential Dermapharm investors.

The financial performance of Dermapharm Holding Company in 2024 and the outlook for 2025 provide additional context. The company reported a 4.0% revenue increase to EUR 1,180.8 million in 2024, with adjusted EBITDA rising by 1.7% to EUR 315.6 million. For 2025, Dermapharm anticipates consolidated revenue between EUR 1,160 million and EUR 1,200 million and adjusted EBITDA between EUR 322 million and EUR 332 million. Such positive financial indicators may influence investor sentiment and potentially lead to further shifts in public and institutional Dermapharm ownership.

Key Stakeholders

Wilhelm Beier and Family, through Themis Beteiligungs AG, are the major stakeholders, holding over 70% of the shares as of March 2025. The high level of insider ownership suggests strong confidence in the company's future. This ownership structure significantly influences strategic decisions and market perception.

Recent Acquisitions

Dermapharm has expanded its portfolio through acquisitions, including Allergopharma, C³ Group, and a stake in Montavit. These strategic moves aim to diversify the company's offerings and strengthen its market position. These acquisitions impact the company's valuation and attractiveness to Dermapharm investors.

Financial Performance

In 2024, Dermapharm saw a 4.0% increase in revenue, reaching EUR 1,180.8 million. Adjusted EBITDA rose by 1.7% to EUR 315.6 million. The company forecasts continued revenue growth in 2025, with adjusted EBITDA expected between EUR 322 million and EUR 332 million.

Ownership Trends

The founder's sustained influence, insider share purchases, and positive financial results suggest a stable and confident outlook. These factors may influence future ownership dynamics. For more information about Dermapharm, check out the Target Market of Dermapharm Holding.

Dermapharm Holding Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs